News Daily News REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD L.A. McKeown January 24, 2023
News Conference News ISET 2023 BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions Caitlin E. Cox January 20, 2023
News Conference News ISET 2023 For Vascular Labs, Accreditation Drives Quality and Objectivity Caitlin E. Cox January 17, 2023
News Daily News Brachytherapy Remains an Option for DES In-Stent Restenosis Yael L. Maxwell January 12, 2023
News Daily News CT Angiography Is Increasing in England, but Downstream Tests Are Not Michael O'Riordan January 12, 2023
News Daily News Routine Coronary Tests Prior to Kidney Transplant Questioned Yael L. Maxwell January 05, 2023
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2022 Shelley Wood January 03, 2023
News Opinion Conversations in Cardiology Conversations in Cardiology: ISCHEMIA’s Lasting Fallout December 29, 2022
News Daily News Anatomic Disease After PCI Linked With Worse Outcomes: VA CART Michael O'Riordan December 22, 2022
News Daily News FFR Pullback Measure Linked to Likelihood of Angina Relief After PCI Todd Neale December 02, 2022
News Daily News P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis Todd Neale November 21, 2022
News Daily News Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD Yael L. Maxwell November 21, 2022
News Conference News Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices L.A. McKeown November 18, 2022
News Daily News Many STEMI Patients Not Treated Within National Time Goals Michael O'Riordan November 15, 2022
News Conference News AHA 2022 Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI Yael L. Maxwell November 10, 2022
News Conference News AHA 2022 Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI L.A. McKeown November 07, 2022
News Conference News AHA 2022 BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI Shelley Wood November 06, 2022
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022